Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance
1Influenza Virus Research Center, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208-0011, Japan.
Abstract:
The influenza virus RNA-dependent RNA polymerase is highly conserved among influenza A, B, C, and D viruses. It comprises three subunits: polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2), and polymerase acidic protein (PA) in influenza A and B viruses or polymerase 3 protein (P3) in influenza C and D viruses. Because this polymerase is essential for influenza virus replication, it has been considered as a target for antiviral agents. Recently, several polymerase inhibitors that target each subunit have been developed. This review discusses the mechanism of action, antiviral activity, and emergence of resistance to three inhibitors approved for the treatment of influenza or in late-phase clinical trials: the PB1 inhibitor favipiravir, the PB2 inhibitor pimodivir, and the PA inhibitor baloxavir marboxil.
Insights
Influenza virus polymerase inhibitors like favipiravir, pimodivir, and baloxavir marboxil target essential viral replication proteins. This review examines their mechanisms, efficacy, and resistance for influenza treatment.
Area of Science:
- Virology
- Pharmacology
Background:
- The influenza virus RNA-dependent RNA polymerase is a conserved, essential target for antiviral development.
- It consists of subunits PB1, PB2, and PA (influenza A/B) or P3 (influenza C/D).
Purpose of the Study:
- To review the mechanism of action, antiviral activity, and resistance of key influenza polymerase inhibitors.
- To discuss favipiravir (PB1 inhibitor), pimodivir (PB2 inhibitor), and baloxavir marboxil (PA inhibitor).
Main Methods:
- Literature review of scientific publications and clinical trial data.
- Analysis of inhibitor mechanisms, efficacy against influenza viruses, and resistance profiles.
Main Results:
- Favipiravir, pimodivir, and baloxavir marboxil demonstrate varying antiviral activities and resistance emergence patterns.
- Each inhibitor targets a specific subunit of the influenza polymerase, impacting viral replication.
Conclusions:
- Influenza polymerase inhibitors represent a promising therapeutic strategy against influenza infections.
- Understanding their mechanisms and resistance is crucial for effective clinical application and future drug development.
More Related Videos
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Leaky Scanning
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...


